Libido and arousal — both genders
PT-141 + Kisspeptin-10 — central-acting desire and reproductive hormone signaling.
About this protocol
A two-mechanism approach to libido that operates centrally — distinct from the vascular-only mechanism of PDE5 inhibitors. PT-141 activates melanocortin pathways involved in sexual motivation; Kisspeptin-10 stimulates hypothalamic GnRH pulsatility, supporting the underlying reproductive hormone axis.
Who it's for: Men and women noticing libido or desire decline — particularly when central, motivational components feel as relevant as performance.
What's in this protocol
SPARK pairs 2 compounds:
PT-141
Bremelanotide
FDA-approved as Vyleesi for hypoactive sexual desire disorder in premenopausal women; studied off-label for men. Activates melanocortin receptors MC3R and MC4R in the central nervous system — a desire-pathway mechanism distinct from PDE5.
Used for
Kisspeptin-10
Kisspeptin-10 (KISS1 gene peptide)
Naturally occurring neuropeptide that acts on the hypothalamus to stimulate GnRH pulsatility — driving downstream LH, FSH, and sex hormone production. Central role in reproductive endocrinology.
Used for
What members are working toward
The following reflects areas of interest commonly reported by members and studied in the clinical literature. Results depend on individual health status, labs, and physician-directed care. Nothing below constitutes a treatment claim.
Centrally-acting desire support
Unlike PDE5 inhibitors that act on the vascular system, PT-141 works through brain pathways involved in sexual motivation — a mechanism studied for both men and women.
HPG-axis signaling
Kisspeptin-10 supports the upstream signaling that drives endogenous sex hormone production — addressing the foundation rather than just the symptom.
Both genders
PT-141 is FDA-approved for women and used off-label for men. Kisspeptin-10 has been studied in both populations. SPARK is the single SKU that fits both.
Distinct from PDE5 mechanism
Members on PDE5 inhibitors who want desire support (not just performance support) often pair SPARK with DRIVE ON-DEMAND — different mechanisms, complementary effects.
Relevant bloodwork markers
SPARK is prescribed and monitored against bloodwork. The Halftime Baseline panel ($249, separate onboarding deliverable) covers the relevant markers below.
How to subscribe
Available at every tier
- Foundation $199/mo — pick SPARK as your 1 protocol
- Optimizer $349/mo — pair SPARK with 1 other protocol
- Elite $549/mo — stack SPARK with 2 other protocols
Premium add-ons (VITALIZE, IMMUNE GUARD, MITOCORE) bill separately on top of any tier. The Halftime Baseline bloodwork panel ($249) is a separate onboarding deliverable, available at any tier.
Join the waitlistLaunching July 1, 2026
All prescriptions require physician evaluation. Compounded medications are not FDA-approved. Individual results vary. This is not medical advice.